|

QL1706 Clinical Trials

14 actively recruiting trials

Also known as: Cisplatin, GEMOX, Iparomlimab and Tuvonralimab，PSB205, Lenvatinib, Radiation, Taxol

Other14 trials

A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Phase 2
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Phase 3
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Phase 1/2
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Phase 2
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
N/A
Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors
Phase 1/2
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Phase 2
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Phase 2
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Phase 3
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Phase 2
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Phase 2
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Phase 2
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Phase 2
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.